MRTX News and Press, Mirati Therapeutics Inc. From 08/03/22

Mirati Therapeutics press release ( NASDAQ: MRTX ): Q2 GAAP EPS of -$3.18 beats by $0.32 . Revenue of $5.36M beats by $4.98M . For further details see: Mirati Therapeutics GAAP EPS of -$3.18 beats by $0.32, revenue of $5.36M beats by $4.98M

Mirati Therapeutics Reports Second Quarter 2022 Financial Results and Recent Corporate Updates PR Newswire SAN DIEGO , Aug. 3, 2022 /PRNewswire/ -- Mirati Therapeutics, Inc. (NASDAQ: MRTX), a clinical-stage targeted oncology company, today reported fi...

Mirati Therapeutics to Report Second Quarter 2022 Financial Results and Recent Corporate Updates PR Newswire SAN DIEGO , July 20, 2022 /PRNewswire/ -- Mirati Therapeutics, Inc. (NASDAQ: MRTX), a clinical-stage targeted oncology company, will announce ...

The Health Care sector of the S&P 500 was in the red this month, with the Health Care Select Sector SPDR ETF ( XLV ) finishing 3% lower . The top five gainers in the health care sector (stocks with a market cap of over $2B) were: Turning Point Therapeutics...

Baker Brothers’ 13F portfolio value decreased from $20.55B to $17.40B this quarter. Horizon Therapeutics was increased while decreasing Legend Biotech. The top three positions are Seagen, Incyte Corporation, and BeiGene, and they add up to almost 68% of the portfolio. ...

After the most aggressive growth phase, you can continue to make substantially more, if and only if, the drug later becomes a blockbuster in commercialization. After years of innovation, Mirati Therapeutics is poised to send its crown jewel (adagrasib) to the market. Adagrasib has...

Mirati will probably not get accelerated approval for adagrasib in 2nd line NSCLC. This will delay their program for two years. However, much of their data is stronger than Amgen's lumakras. For further details see: Mirati: Not Looking Good In 2022, But Stronger Prospect...

Shares of Mirati Therapeutics (NASDAQ: MRTX) were skyrocketing 37.2% this week as of the market close on Thursday, according to data from S&P Global Market Intelligence . This huge gain came after the company presented data at the 2022 American Society of Clinical Oncology a...

Mirati Therapeutics (NASDAQ:MRTX) jumped more than 25% in the morning hours Tuesday to record the biggest intraday gain  since June 2019 after JMP Securities upgraded the clinical-stage oncology company to Market Outperform from Market Perform. The analyst Silvan Tuerkcan point...

Gainers: Mirati Therapeutics (MRTX) +23%. CymaBay Therapeutics (CBAY) +16%. Veru (VERU) +9%. Kodiak Sciences (KOD) +8%. Allarity Therapeutics (ALLR) +7%. Losers: Verastem (VSTM) -12%. Delcath Systems (DCTH) -11%. Vicarious Surgical (RBOT) -8%. CEL-...